Viatris Inc. VTRS · Stock Open Viatris Inc. in new tab

Viatris shares fell 6.9% after the quarter as investors reacted negatively to the cautious outlook driven by ongoing manufacturing disruptions and a heightened regulatory burden at its Nashik facility, dampening confidence despite raised guidance.

• Total revenues grew 3.5% year-over-year to $3.8 billion, reflecting moderate operational growth.
• Adjusted EBITDA reached $1.2 billion, and adjusted EPS was $0.69 per share, both in line with guidance.
• The company raised its 2026 financial guidance midpoint but highlighted intermittent manufacturing disruptions at Nashik following a Q1 fire and FDA inspection in May.
• Initiated a comprehensive remediation plan to address FDA observations, adding near-term execution risk.
• Commercial execution was solid in Greater China and North America, supported by new product approvals and pipeline progress, though these positives were overshadowed by operational challenges.